2020 American Transplant Congress
Effect of Glecaprevir/Pibrentasvir on Weight-Adjusted Tacrolimus Trough/Dose Ratios in Heart and Kidney Recipients
*Purpose: An innovative strategy to meet the demands of patients requiring heart or kidney transplantation is the acceptance of hepatitis C viremic organs. Direct acting…2020 American Transplant Congress
Utilization of Organs from Donors Exposed to Hepatitis C: ? Standard of Care
*Purpose: To report the results of a clinical program to utilize livers and kidneys from donors exposed to Hepatitis C.*Methods: We initially started to explore…2020 American Transplant Congress
Multi-Organ Procurement Organization Review of the Impact of Reactive Anti-HCV and HCV NAT Results
LifeShare Transplant Donor Services of Oklahoma, Oklahoma City, OK
*Purpose: Previously a single organ procurement organization (OPO) reviewed data from a 15 month cohort (1/1/2016 to 3/31/17) and concluded that donors who tested positive…2020 American Transplant Congress
Utilization of Kidneys from Deceased Donors with Positive Hepatitis C Nucleic Acid Amplification Testing (HCV NAT+)
Columbia University, New York, NY
*Purpose: With modern direct-acting antiviral agents, transplantation of kidneys from HCV NAT+ deceased donors for recipients with or without HCV has expanded the kidney supply.…2020 American Transplant Congress
Evaluating the Effect of HCV Status on the KDPI in the Era of DAA Therapy
*Purpose: The association between KDPI and kidney graft outcomes is limited in the era of DAA therapy.*Methods: We analyzed adult renal transplants, at the University…2020 American Transplant Congress
Viral Kinetics of De Novo HCV Infection and Response to Antiviral Therapy in Liver and Kidney Transplant Recipients Receiving HCV-Viremic Donors
*Purpose: There is general agreement that expanded use of organs from HCV-viremic donors is desirable, including in recipients without HCV infection. However, the optimal treatment…2020 American Transplant Congress
Transplanting Livers from Hepatitis C Virus Positive Donors; Is it Worth the Risk?
*Purpose: Before the introduction of Direct-Acting Antivirals (DAAs), only selected organs from Hepatitis C virus (HCV) positive donors were successfully transplanted into HCV positive recipients.…2020 American Transplant Congress
Hepatitis C Antibody Seroconversion in Kidney Transplant Patients from HCV Antibody Positive/NAT Negative Donors Does Not Deteriorate Renal Allograft Outcome
Loma Linda University, Transplant Institute, San Bernadino, CA
*Purpose: Prior studies have shown that almost 50% of kidney transplant patients from hepatitis C Ab+/NAT - donors have seroconverted but its impact on renal…2020 American Transplant Congress
HCV Viremic Kidneys for Uninfected Recipients with DAA Treatment Offers Sustained Virologic Response
Montefiore Medical Center, Bronx, NY
*Purpose: Development of direct acting anti-viral medications (DAA) have offered cure rates for hepatitis C infection (HCV) approaching 100%. This has provided the ability to…2020 American Transplant Congress
Real-World Experiences in the Transplantation of Hepatitis C Positive Kidneys
*Purpose: With advancements of direct-acting antivirals, transplantation of HCV-NAT+ (HCV+) organs to HCV-negative (HCV-) recipients has been used to decrease wait times without apparent sacrifice…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 28
- Next Page »